^
+ Follow TEVA AND IVAS Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 184159
                    [Title] => US court upholds patent for drug
                    [Summary] => A US federal court recently upheld the patent for Fosomax, a blockbuster osteoporosis drug produced by Merck, a US pharmaceuticals group which was being challenged by two generic drug makers to enable them to make cheaper versions of the drug.


A Financial Times report from New York said a district court in Delaware ruled against Teva Pharmaceuticals and Ivas Pharmaceutical, two Israeli companies which were attempting to launch inexpensive versions of Fosomax. Merck’s patent on the drug, which generated $455 million in sales last quarter, is valid until August 2007.
[DatePublished] => 2002-11-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Business [SectionUrl] => business [URL] => ) ) )
TEVA AND IVAS
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 184159
                    [Title] => US court upholds patent for drug
                    [Summary] => A US federal court recently upheld the patent for Fosomax, a blockbuster osteoporosis drug produced by Merck, a US pharmaceuticals group which was being challenged by two generic drug makers to enable them to make cheaper versions of the drug.


A Financial Times report from New York said a district court in Delaware ruled against Teva Pharmaceuticals and Ivas Pharmaceutical, two Israeli companies which were attempting to launch inexpensive versions of Fosomax. Merck’s patent on the drug, which generated $455 million in sales last quarter, is valid until August 2007.
[DatePublished] => 2002-11-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Business [SectionUrl] => business [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with